Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2008 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: December 10, 1999
Last updated: April 29, 2009
Last verified: December 2008

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Combining hyperthermia with chemotherapy and interferon alfa may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects of cisplatin, gemcitabine, interferon alfa, and whole-body hyperthermia and how well they work in treating patients with metastatic, recurrent, or refractory cancer.

Condition Intervention Phase
Unspecified Adult Solid Tumor, Protocol Specific
Biological: recombinant interferon alfa
Drug: cisplatin
Drug: gemcitabine hydrochloride
Procedure: hyperthermia treatment
Phase 1
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase I-II Clinical Trial of Cisplatin (Platinol) Followed by Gemcitabine HCl (Gemzar) in Combination With Mild, Fever-Range Whole Body Hyperthermia (LL-WBH) at 40C in Patients With Advanced Malignancies

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Response duration [ Designated as safety issue: No ]
  • Duration of stable disease [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]
  • Progression-free survival [ Designated as safety issue: No ]
  • Time to response [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: August 1999
Estimated Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the toxicity and tumor response in patients with metastatic, recurrent, or refractory malignancies treated with cisplatin, gemcitabine, interferon alfa, and long-duration, low temperature whole body hyperthermia (LL-WBH).

OUTLINE: This is a dose escalation study of cisplatin.

  • Phase I and II: Patients receive gemcitabine IV over 30 minutes on day 1 and 8. Patients receive cisplatin IV over 6 hours on day 15, followed by subcutaneous interferon alfa on days 16 and 17. Patients undergo long-duration, low temperature whole body hyperthermia over 6 hours plus gemcitabine over 30 minutes on day 17. Courses repeat every 5 weeks in the absence of disease progression or unacceptable toxicity.
  • Phase I: Cohorts of 3-6 patients receive escalating doses of cisplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose limiting toxicity. The MTD of cisplatin is used for phase II study.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed metastatic, recurrent, or refractory carcinoma
  • Measurable disease by CT, MRI, or physical examination
  • No brain metastases or other CNS disorders



  • 18 and over

Performance status:

  • Karnofsky 60-100%

Life expectancy:

  • At least 12 weeks


  • Absolute granulocyte count at least 1,500/mm^3
  • Platelet count at least 90,000/mm^3
  • Bone marrow cellularity normal on bone marrow biopsy
  • No coagulopathy disorder


  • Bilirubin no greater than 2.0 mg/dL
  • SGOT no greater than 2 times upper limit of normal
  • PT less than 14 seconds
  • PTT less than 35 seconds
  • No inadequate liver function (no greater than 20% involvement)


  • Creatinine no greater than 1.8 mg/dL
  • Creatinine clearance at least 45 mL/min
  • BUN no greater than 25 mg/dL


  • Adequate cardiac function documented by history, physical exam, or stress exercise test (MUGA or ECHO) with resting blood pressure and heart rate increasing appropriately with exercise
  • LVEF at least 45%
  • No prior myocardial infarction
  • No symptomatic coronary artery disease
  • No angina
  • No significant arrhythmia
  • No uncontrolled hypertension
  • No thromboembolic disease


  • FEV_1 at least 70% of predicted
  • Arterial PO_2 at least 60 mmHg on room air
  • No massive (greater than 30% involvement) lung disease
  • DLCO greater than 50% of predicted


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • HIV negative
  • No seizure disorders
  • No significant emotional instability
  • No history of malignant hyperthermia following general anesthesia
  • No other concurrent medical illness that would prevent compliance


Biologic therapy:

  • Not specified


  • Prior chemotherapy allowed

Endocrine therapy:

  • Not specified


  • Not specified


  • At least 6 days since major thoracic or abdominal surgery


  • No concurrent cardiac glycosides, antiangina drugs, arrhythmia drugs, anticoagulants, thrombolytic agents, adrenal corticosteroids, or aspirin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00004063

United States, Texas
University of Texas Health Science Center at Houston Recruiting
Houston, Texas, United States, 77225
Contact: Joan M.C. Bull, MD    713-500-6820   
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Study Chair: Joan M.C. Bull, MD The University of Texas Health Science Center, Houston
  More Information

Additional Information:
No publications provided

Responsible Party: Joan M.C. Bull, University of Texas Health Science Center at Houston Identifier: NCT00004063     History of Changes
Obsolete Identifiers: NCT00005929
Other Study ID Numbers: CDR0000067264  UTHSC-MS-99116  NCI-V99-1561 
Study First Received: December 10, 1999
Last Updated: April 29, 2009
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses processed this record on February 04, 2016